HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazuhiko Ezawa Selected Research

Infliximab (Remicade)

5/2018IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazuhiko Ezawa Research Topics

Disease

6Rheumatoid Arthritis
05/2018 - 01/2008
1Dementia (Dementias)
07/2013

Drug/Important Bio-Agent (IBA)

2Etanercept (Enbrel)FDA Link
07/2014 - 12/2010
1Interleukin-6 (Interleukin 6)IBA
05/2018
1Infliximab (Remicade)FDA Link
05/2018
1Proteins (Proteins, Gene)FDA Link
04/2015
1Peptides (Polypeptides)IBA
04/2015
1AntibodiesIBA
04/2015
1Tumor Necrosis Factor InhibitorsIBA
03/2015
1tocilizumab (atlizumab)FDA Link
03/2015
1Adalimumab (Humira)FDA Link
07/2014
1Tacrolimus (Prograf)FDA LinkGeneric
01/2008
1Antirheumatic Agents (DMARD)IBA
01/2008

Therapy/Procedure

1Medical Day Care (Partial Hospitalization)
07/2013
1Long-Term Care
07/2013
1Aftercare (After-Treatment)
12/2010
1Orthopedic Procedures
12/2010
1Renal Dialysis (Hemodialysis)
01/2008